- The Company plans to work with the FDA to design a Phase 3 program in moderate-to-high systemic disease activity patients to begin in 2023, ahead of expectations - DUBLIN--(BUSINESS WIRE)--Horizon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback